Biotechnology company Sequenom announced a $14 million settlement last week with a group of shareholders that filed a class-action lawsuit against the company in April after their stock plummeted 80 percent. The company had announced that data and results from trials and tests of their product SEQureDX, a prenatal test for Down syndrome that eliminates the risks of amniocentesis, had been improperly handled, prompting the price drop and lawsuit.